{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-002841","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.124219+00:00","generated_at":"2026-06-18T03:26:47.950456+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ENDRA Life Sciences reports Q4 net loss $3.3M, cash $4.9M; advances TAEUS regulatory submission","bullets":["Net loss Q4 2022 $3.3M ($1.04/share) vs Q4 2021 $3.1M ($1.48/share); FY2022 net loss $13.2M ($4.56/share).","Cash and equivalents $4.9M at Dec 31, 2022; company notes exposure to SVB failure but deposits spread across multiple banks.","Over 100 TAEUS scans at clinical sites in 2022; interactive guidance tool deployed to improve operator performance.","Plans to submit De Novo request to FDA for TAEUS liver device; renewed GE HealthCare collaboration through Dec 2024.","Operating expenses up to $3.3M in Q4 and $13.2M in FY, driven by product development and European commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-002841","json":"https://secwatch.observer/filing/0001654954-23-002841.json","markdown":"https://secwatch.observer/filing/0001654954-23-002841.md","text":"https://secwatch.observer/filing/0001654954-23-002841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:26:47.950456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8609c7394609e418b53f4f8df1d86f133b40626","claim":"ENDRA Life Sciences Inc. reported the fourth quarter of 2022 results: net income Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, EPS $1.04 per share.","evidence_excerpt":"Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, compared with a net loss of $3.1 million, or $1.48 per share, in the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Net income","value":"Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share"},{"label":"EPS","value":"$1.04 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b6f1e447ad69bc77d1b2024818cd09329cd80f9c","claim":"ENDRA Life Sciences Inc. reported the year ended December 31, 2022 results: net income Net loss in 2022 was $13.2 million, or $4.56 per share, EPS $4.56 per share.","evidence_excerpt":"Net loss in 2022 was $13.2 million, or $4.56 per share, compared with a net loss of $11.2 million, or $5.55 per share, in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423002841/0001654954-23-002841-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss in 2022 was $13.2 million, or $4.56 per share"},{"label":"EPS","value":"$4.56 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}